- Home
- Media Center
- Press releases
- Corporate
Corporate
Johnson & Johnson Completes Acquisition of V-Wave
Adds V-Wave’s Novel and Minimally Invasive Ventura® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular Disease
Johnson & Johnson Announces Collaborative Effort with USAID to Strengthen the Health Workforce Across Latin America and the Caribbean
Memorandum of Understanding will support the Americas Health Corps in its goal to train 500,000 health workers to help build strong and resilient health systems and bring more communities closer to care
Johnson & Johnson to invest more than $2 billion in new, advanced technology manufacturing facility in North Carolina to support robust portfolio growth
Johnson & Johnson (NYSE: JNJ) today announced an investment of more than $2 billion to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. The new facility will expand production of the Company’s portfolio and pipeline of innovative biologics in support of Johnson & Johnson’s broader plan to advance more than 70 novel therapy and product expansion filings and launches by the end of the decade.
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan Red River Increased its Settlement Commitment by $1.75 Billion to Approximately $8 Billion
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States